vs
Ategrity Specialty Insurance Co Holdings（ASIC）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Ategrity Specialty Insurance Co Holdings的季度营收约是MESA LABORATORIES INC的1.8倍（$116.1M vs $65.1M），Ategrity Specialty Insurance Co Holdings净利率更高（19.5% vs 5.6%，领先13.9%）
Ategrity Specialty Insurance Co Holdings是一家特种保险控股企业，提供商业财产及意外伤害保险解决方案，主营超额与盈余线保险业务，服务美国本土建筑、医疗、小型企业等细分领域，为标准保险公司通常不承接的特殊风险提供定制化保单。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
ASIC vs MLAB — 直观对比
营收规模更大
ASIC
是对方的1.8倍
$65.1M
净利率更高
ASIC
高出13.9%
5.6%
损益表 — Q3 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $116.1M | $65.1M |
| 净利润 | $22.7M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 25.6% | 12.2% |
| 净利率 | 19.5% | 5.6% |
| 营收同比 | — | 3.6% |
| 净利润同比 | — | 316.6% |
| 每股收益（稀释后） | $0.45 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASICMLAB
| Q4 25 | — | $65.1M | ||
| Q3 25 | $116.1M | $60.7M | ||
| Q2 25 | $101.8M | $59.5M | ||
| Q1 25 | — | $62.1M | ||
| Q4 24 | — | $62.8M | ||
| Q3 24 | — | $57.8M | ||
| Q2 24 | — | $58.2M | ||
| Q1 24 | — | $58.9M |
净利润ASICMLAB
| Q4 25 | — | $3.6M | ||
| Q3 25 | $22.7M | $2.5M | ||
| Q2 25 | $17.6M | $4.7M | ||
| Q1 25 | — | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $3.4M | ||
| Q1 24 | — | $-254.6M |
毛利率ASICMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率ASICMLAB
| Q4 25 | — | 12.2% | ||
| Q3 25 | 25.6% | 7.8% | ||
| Q2 25 | 21.9% | 5.1% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | -460.6% |
净利率ASICMLAB
| Q4 25 | — | 5.6% | ||
| Q3 25 | 19.5% | 4.1% | ||
| Q2 25 | 17.3% | 8.0% | ||
| Q1 25 | — | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | — | -432.2% |
每股收益（稀释后）ASICMLAB
| Q4 25 | — | $0.65 | ||
| Q3 25 | $0.45 | $0.45 | ||
| Q2 25 | $0.39 | $0.85 | ||
| Q1 25 | — | $-1.30 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | — | $0.63 | ||
| Q2 24 | — | $0.62 | ||
| Q1 24 | — | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.3M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $588.6M | $186.7M |
| 总资产 | $1.4B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ASICMLAB
| Q4 25 | — | $29.0M | ||
| Q3 25 | $34.3M | $20.4M | ||
| Q2 25 | $23.5M | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M | ||
| Q1 24 | — | $28.2M |
总债务ASICMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益ASICMLAB
| Q4 25 | — | $186.7M | ||
| Q3 25 | $588.6M | $178.5M | ||
| Q2 25 | $559.7M | $172.5M | ||
| Q1 25 | — | $159.8M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $161.5M | ||
| Q2 24 | — | $150.7M | ||
| Q1 24 | — | $145.4M |
总资产ASICMLAB
| Q4 25 | — | $434.8M | ||
| Q3 25 | $1.4B | $430.4M | ||
| Q2 25 | $1.4B | $435.7M | ||
| Q1 25 | — | $433.3M | ||
| Q4 24 | — | $433.3M | ||
| Q3 24 | — | $454.1M | ||
| Q2 24 | — | $440.4M | ||
| Q1 24 | — | $446.8M |
负债/权益比ASICMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $41.1M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 1.81× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流ASICMLAB
| Q4 25 | — | $18.8M | ||
| Q3 25 | $41.1M | $8.2M | ||
| Q2 25 | $50.8M | $1.9M | ||
| Q1 25 | — | $12.7M | ||
| Q4 24 | — | $18.1M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | — | $10.7M | ||
| Q1 24 | — | $12.9M |
自由现金流ASICMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率ASICMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度ASICMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率ASICMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | 1.81× | 3.32× | ||
| Q2 25 | 2.88× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIC
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
